Pfizer Inc (PFE)vsTeck Resources Ltd Class B (TECK)
PFE
Pfizer Inc
$25.68
-1.40%
HEALTHCARE · Cap: $150.92B
TECK
Teck Resources Ltd Class B
$60.76
-2.02%
BASIC MATERIALS · Cap: $29.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Pfizer Inc generates 410% more annual revenue ($63.32B vs $12.41B). TECK leads profitability with a 14.9% profit margin vs 11.8%. TECK appears more attractively valued with a PEG of 5.47. TECK earns a higher WallStSmart Score of 73/100 (B).
PFE
Buy55
out of 100
Grade: C
TECK
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+29.4%
Fair Value
$37.48
Current Price
$25.68
$11.80 discount
Margin of Safety
+9.1%
Fair Value
$66.42
Current Price
$60.76
$5.66 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.6%
Large-cap with strong market position
Reasonable price relative to book value
Generating 2.2B in free cash flow
Strong operational efficiency at 39.8%
Revenue surging 72.2% year-over-year
Earnings expanding 128.8% YoY
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 10.1%
Grey zone — moderate risk
ROE of 5.9% — below average capital efficiency
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : PFE
The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.
Bull Case : TECK
The strongest argument for TECK centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 72.2% demonstrates continued momentum.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : TECK
The primary concerns for TECK are Altman Z-Score, Return on Equity, PEG Ratio.
Key Dynamics to Monitor
PFE profiles as a value stock while TECK is a growth play — different risk/reward profiles.
TECK carries more volatility with a beta of 1.57 — expect wider price swings.
TECK is growing revenue faster at 72.2% — sustainability is the question.
PFE generates stronger free cash flow (2.2B), providing more financial flexibility.
Bottom Line
TECK scores higher overall (73/100 vs 55/100) and 72.2% revenue growth. PFE offers better value entry with a 29.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Teck Resources Ltd Class B
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Teck Resources Limited is dedicated to exploring, acquiring, developing and producing natural resources in Asia, Europe and North America. The company is headquartered in Vancouver, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?